Protective Day

Avobenzone, Homosalate, Octinoxate, Octocrylene


Usana Health Sciences, Inc.
Human Otc Drug
NDC 51861-060
Protective Day also known as Avobenzone, Homosalate, Octinoxate, Octocrylene is a human otc drug labeled by 'Usana Health Sciences, Inc.'. National Drug Code (NDC) number for Protective Day is 51861-060. This drug is available in dosage form of Lotion. The names of the active, medicinal ingredients in Protective Day drug includes Avobenzone - 30 mg/mL Homosalate - 100 mg/mL Octinoxate - 75 mg/mL Octocrylene - 20 mg/mL . The currest status of Protective Day drug is Active.

Drug Information:

Drug NDC: 51861-060
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Protective Day
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Avobenzone, Homosalate, Octinoxate, Octocrylene
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Usana Health Sciences, Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Lotion
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:AVOBENZONE - 30 mg/mL
HOMOSALATE - 100 mg/mL
OCTINOXATE - 75 mg/mL
OCTOCRYLENE - 20 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Aug, 2017
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 09 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part352
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2024
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
UNII:
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
51861-060-001 BOTTLE in 1 CARTON (51861-060-00) / 30 mL in 1 BOTTLE01 Aug, 2017N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose sunscreen sunscreen sunscreen sunscreen

Product Elements:

Protective day avobenzone, homosalate, octinoxate, octocrylene water butylene glycol isopropyl lauroyl sarcosinate pentylene glycol mica ethylhexyl palmitate cetostearyl alcohol dimethicone polysorbate 60 soybean black olive watermelon lens culinaris fruit apple eleuthero asian ginseng american ginseng shea butter rosa multiflora fruit ceramide np sodium pyrrolidone carboxylate glycerin sodium lactate ceteth-10 phosphate dihexadecyl phosphate carbomer interpolymer type a (allyl sucrose crosslinked) carboxypolymethylene silicon dioxide citric acid monohydrate potassium hydroxide avobenzone avobenzone homosalate homosalate octinoxate octinoxate octocrylene octocrylene

Indications and Usage:

Uses • helps prevent sunburn. • if used as directed with other sun protection measures (see directions), decreases the risk of skin cancer and early skin aging caused by the sun.

• shake well and apply a pearl-sized amount to face and neck • apply generously and evenly 15 minutes before sun exposure • reapply at least every 2 hours • use a water resistant sunscreen if swimming or sweating • sun protection measures . spending time in the sun increases your risk of skin cancer and early skin aging. to decrease this risk, regularly use a sunscreen with a broad spectrum spf value of 15 or higher and other sun protection measures including: • limit time in the sun, especially from 10 a.m. - 2 p.m. • wear long-sleeved shirts, pants, hats, and sunglasses • children under 6 months of age: ask a doctor

Warnings:

Warnings for external use only. do not use • on damaged or broken skin. when using this product • keep out of eyes. rinse with water to remove. stop use and ask a doctor if • rash occurs. keep out of reach of children. if product is swallowed, get medical help or contact a poison control center right away.

Package Label Principal Display Panel:

Package labeling: protective day lotion

Further Questions:

Questions or comments? call toll free 1-800-950-9595


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.